$397.48
Vertex Pharmaceuticals Incorporated is a biotechnology company that develops and commercializes treatments for cystic fibrosis and other serious medical conditions.
Insights on Vertex Pharmaceuticals Incorporated
Revenue is up for the last 2 quarters, 2.48B → 2.51B (in $), with an average increase of 1.4% per quarter
Netprofit is down for the last 2 quarters, 1.03B → 968.8M (in $), with an average decrease of 6.4% per quarter
In the last 1 year, Novo Nordisk A/s has given 51.5% return, outperforming this stock by 34.3%
In the last 3 years, Novo Nordisk A/s has given 241.4% return, outperforming this stock by 156.9%
0.94%
Downside
Day's Volatility :1.48%
Upside
0.55%
19.49%
Downside
52 Weeks Volatility :28.63%
Upside
11.36%
Period | Vertex Pharmaceuticals Incorporated | Sector (Health Care) | Index (NASDAQ Composite) |
---|---|---|---|
3 Months | -7.55% | 0.5% | 3.1% |
6 Months | 11.94% | 13.6% | 26.0% |
1 Year | 17.19% | 5.7% | 31.2% |
3 Years | 84.52% | 14.2% | 13.0% |
Market Capitalization | 103.6B |
Book Value | $68.22 |
Earnings Per Share (EPS) | 13.91 |
PE Ratio | 28.81 |
PEG Ratio | 0.53 |
Wall Street Target Price | 466.14 |
Profit Margin | 36.68% |
Operating Margin TTM | 37.97% |
Return On Assets TTM | 13.17% |
Return On Equity TTM | 22.99% |
Revenue TTM | 9.9B |
Revenue Per Share TTM | 38.3 |
Quarterly Revenue Growth YOY | 9.3% |
Gross Profit TTM | 5.3B |
EBITDA | 4.5B |
Diluted Eps TTM | 13.91 |
Quarterly Earnings Growth YOY | 0.18 |
EPS Estimate Current Year | 16.75 |
EPS Estimate Next Year | 18.21 |
EPS Estimate Current Quarter | 4.1 |
EPS Estimate Next Quarter | 4.1 |
What analysts predicted
Upside of 17.27%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 3.0B | ↑ 22.46% |
Net Income | 2.1B | ↑ 695.83% |
Net Profit Margin | 68.8% | ↑ 58.21% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 4.2B | ↑ 36.59% |
Net Income | 1.2B | ↓ 43.88% |
Net Profit Margin | 28.27% | ↓ 40.53% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 6.2B | ↑ 49.07% |
Net Income | 2.7B | ↑ 130.43% |
Net Profit Margin | 43.7% | ↑ 15.43% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 7.6B | ↑ 22.06% |
Net Income | 2.3B | ↓ 13.63% |
Net Profit Margin | 30.92% | ↓ 12.78% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 8.9B | ↑ 17.91% |
Net Income | 3.3B | ↑ 41.84% |
Net Profit Margin | 37.2% | ↑ 6.28% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 9.8B | ↑ 10.17% |
Net Income | 3.6B | ↑ 8.96% |
Net Profit Margin | 36.79% | ↓ 0.41% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.3B | ↑ 6.29% |
Net Income | 930.5M | ↑ 14.81% |
Net Profit Margin | 39.86% | ↑ 2.96% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.3B | ↓ 1.35% |
Net Income | 818.9M | ↓ 11.99% |
Net Profit Margin | 35.56% | ↓ 4.3% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.4B | ↑ 3.13% |
Net Income | 699.8M | ↓ 14.54% |
Net Profit Margin | 29.47% | ↓ 6.09% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.5B | ↑ 4.99% |
Net Income | 915.7M | ↑ 30.85% |
Net Profit Margin | 36.73% | ↑ 7.26% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.5B | ↓ 0.39% |
Net Income | 1.0B | ↑ 13.06% |
Net Profit Margin | 41.69% | ↑ 4.96% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.5B | ↑ 1.38% |
Net Income | 968.8M | ↓ 6.42% |
Net Profit Margin | 38.48% | ↓ 3.21% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 6.2B | ↑ 76.14% |
Total Liabilities | 1.8B | ↑ 20.42% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 8.3B | ↑ 33.18% |
Total Liabilities | 2.2B | ↑ 23.34% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 11.8B | ↑ 41.27% |
Total Liabilities | 3.1B | ↑ 37.25% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 13.4B | ↑ 14.3% |
Total Liabilities | 3.3B | ↑ 8.73% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 18.2B | ↑ 35.13% |
Total Liabilities | 4.2B | ↑ 27.18% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 22.7B | ↑ 25.23% |
Total Liabilities | 5.1B | ↑ 21.51% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 16.7B | ↑ 7.21% |
Total Liabilities | 3.7B | ↑ 0.77% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 18.2B | ↑ 8.65% |
Total Liabilities | 4.2B | ↑ 15.27% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 19.0B | ↑ 4.54% |
Total Liabilities | 4.5B | ↑ 7.17% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 20.3B | ↑ 7.25% |
Total Liabilities | 4.9B | ↑ 7.42% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 21.7B | ↑ 6.77% |
Total Liabilities | 5.2B | ↑ 6.85% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 22.7B | ↑ 4.62% |
Total Liabilities | 5.1B | ↓ 1.22% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.3B | ↑ 50.34% |
Investing Cash Flow | -202.2M | ↓ 53.81% |
Financing Cash Flow | -71.2M | ↓ 204.12% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.6B | ↑ 23.54% |
Investing Cash Flow | -1.2B | ↑ 511.07% |
Financing Cash Flow | 126.8M | ↓ 278.0% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 3.3B | ↑ 107.32% |
Investing Cash Flow | 99.4M | ↓ 108.05% |
Financing Cash Flow | -505.3M | ↓ 498.57% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.6B | ↓ 18.75% |
Investing Cash Flow | -340.9M | ↓ 443.0% |
Financing Cash Flow | -1.5B | ↑ 192.51% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.1B | ↑ 56.23% |
Investing Cash Flow | -321.1M | ↓ 5.81% |
Financing Cash Flow | -67.7M | ↓ 95.42% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 955.5M | ↓ 16.17% |
Investing Cash Flow | -384.2M | ↑ 524.72% |
Financing Cash Flow | -60.2M | ↓ 226.21% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.1B | ↑ 12.86% |
Investing Cash Flow | 175.6M | ↓ 145.71% |
Financing Cash Flow | 40.2M | ↓ 166.78% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 899.9M | ↓ 16.55% |
Investing Cash Flow | -1.8B | ↓ 1144.19% |
Financing Cash Flow | -294.7M | ↓ 833.08% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.1B | ↑ 26.06% |
Investing Cash Flow | -303.9M | ↓ 83.43% |
Financing Cash Flow | 17.3M | ↓ 105.87% |
Sell
Neutral
Buy
Vertex Pharmaceuticals Incorporated is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Vertex Pharmaceuticals Incorporated | -4.7% | 11.94% | 17.19% | 84.52% | 130.52% |
Moderna, Inc. | -3.99% | 47.66% | -18.37% | -42.11% | 322.35% |
Regeneron Pharmaceuticals, Inc. | -8.6% | 12.46% | 11.47% | 77.72% | 156.63% |
Novo Nordisk A/s | -2.8% | 32.13% | 52.48% | 239.51% | 414.16% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 130.52% | 28.81 | 36.68% |
Moderna, Inc. | Buy | $41.7B | 322.35% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 156.63% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 414.16% | 47.43 | 36.03% |
Vanguard Group Inc
BlackRock Inc
Capital World Investors
FMR Inc
State Street Corporation
AllianceBernstein L.P.
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Organization | Vertex Pharmaceuticals Incorporated |
Employees | 5400 |
CEO | Dr. Jeffrey Marc Leiden M.D., Ph.D. |
Industry | Health Technology |